Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class ASSE: 688621

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Voluntary Disclosure of Phase I Clinical Trial Data of STC008 Injection for the Treatment of Cancer Cachexia in Patients with Advanced Solid Tumors

· Issued by Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A via Shanghai Stock Exchange

Filed with SSE ·

Announcement on Voluntary Disclosure of Phase I Clinical Trial Data of STC008 Injection for the Treatment of Cancer Cachexia in Patients with Advanced Solid Tumors

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A

All Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A news releases